Close Menu

NEW YORK – Adaptive Biotechnologies announced Tuesday after the close of the market preliminary revenues in the range of $84 million to $85 million for fiscal year 2019.

At the midpoint of the range, the unaudited revenues reflect growth of approximately 52 percent over the firm's 2018 revenues. Adaptive said in a statement it expects operating expenses and net loss for the year to increase compared to 2018 but did not say by how much. Other details were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.